Skip to content
GymFinity — Fitness & Beyond
Nutrition8 min read

Mounjaro vs Ozempic: Which Works Better for Weight Loss, and What Happens When You Stop?

Mounjaro (tirzepatide) and Ozempic or Wegovy (semaglutide) are the most talked-about weight-loss medicines in the world. In 2025 they were finally compared head to head. Here is how much weight each one takes off, the side effects, what happens when people stop — and the part of the plan that protects your results either way.

By

Published

Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy, at a higher dose, for weight loss. Tirzepatide is sold as Mounjaro for diabetes and Zepbound for weight loss. Both are weekly injections. Semaglutide copies one gut hormone, GLP-1; tirzepatide acts on two, GLP-1 and GIP. Both reduce appetite and slow stomach emptying, so people eat less.

Which causes more weight loss, Mounjaro or Ozempic?

Weight-loss trials in adults with obesity (without diabetes)
TrialTreatmentWeight change
STEP 1, NEJM 2021 (1,961 adults, 68 weeks)Semaglutide 2.4 mg vs placebo−14.9% vs −2.4%
SURMOUNT-1, NEJM 2022 (2,539 adults, 72 weeks)Tirzepatide 5, 10, 15 mg−15.0%, −19.5%, −20.9%
SURMOUNT-5, NEJM 2025 (751 adults, 72 weeks)Tirzepatide vs semaglutide, head to head−20.2% vs −13.7%; waist −18.4 vs −13.0 cm

For a 100 kg person, that is roughly 14 kg on semaglutide against 20 kg on tirzepatide at the highest tolerated doses. SURMOUNT-5 was open-label and funded by tirzepatide's maker, but the result matches the earlier placebo-controlled trials.

What are the side effects?

  • Stomach and bowel effects are the most common with both: nausea, diarrhoea, vomiting, constipation and reflux, mostly mild to moderate and worst while the dose is being increased.
  • Gallbladder problems: across 76 trials, GLP-1 drugs raised gallbladder and bile duct disease by 37 percent, more at higher doses — see our gallstones guide.
  • Muscle loss: a meaningful share of the weight lost can be muscle unless you strength train and eat enough protein — see our GLP-1 muscle loss guide.
  • Low blood sugar is a risk mainly for people also taking insulin or sulfonylureas.
  • Rarer: pancreatitis. Seek urgent care for severe, persistent abdominal pain spreading to the back.

What happens when you stop Ozempic or Mounjaro?

Most of the weight comes back unless habits have changed. In the STEP 1 extension, 327 people who had lost 17.3 percent on semaglutide stopped treatment; a year later they had regained 11.6 percentage points, about two-thirds of what they lost. In SURMOUNT-4, 670 people who had lost 20.9 percent over 36 weeks on tirzepatide were split: those switched to placebo regained 14.0 percent over the next year, while those who stayed on tirzepatide lost a further 5.5 percent, and 89.5 percent of them kept at least 80 percent of their weight loss. These medicines work like blood pressure tablets: the effect lasts while you take them.

How to protect your results on a GLP-1 drug

  • Strength train two to three times a week from the start; muscle is what keeps your metabolism and strength up as weight falls.
  • Eat enough protein even when appetite is low — prioritise eggs, chicken, fish, daal, dahi and paneer at every meal.
  • Build eating habits you can keep when the dose drops or stops: portions, fewer sweets and sugary drinks, regular meals.
  • Get the medicine only on prescription from a pharmacy you trust. The World Health Organization has warned about falsified semaglutide pens; fakes can contain the wrong dose or something else entirely.
  • Plan with your doctor how long to stay on it and how to come off — slowly, with habits in place.

This article is general information, not medical advice. GLP-1 medicines are prescription drugs: start, change or stop them only with your doctor, and do not use them if you have a personal or family history of medullary thyroid cancer or MEN2, or a history of pancreatitis, unless your doctor advises it.

Frequently Asked Questions

Is Mounjaro better than Ozempic for weight loss?

In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide (Mounjaro, Zepbound) cut weight by 20.2 percent over 72 weeks versus 13.7 percent for semaglutide (Wegovy, Ozempic's drug). Side effects were similar.

Do you regain weight after stopping Ozempic?

Usually, much of it. In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping semaglutide. Strength training, protein and lasting eating habits reduce the regain.

What are the side effects of Mounjaro and Ozempic?

Mostly nausea, diarrhoea, vomiting and constipation, worst while the dose is being increased. Both also raise the risk of gallbladder problems, and much of the weight lost can be muscle without strength training.

How long do you need to take these injections?

The effect lasts while you take them. In SURMOUNT-4, people who stayed on tirzepatide kept losing weight while those switched to placebo regained 14 percent in a year. Decide the plan with your doctor.

Can I lose weight without Ozempic?

Yes. A steady calorie deficit, enough protein, strength training and daily activity work for most people, more slowly. The medicines help people with obesity who haven't succeeded with lifestyle changes alone.

Sources

  1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021
  2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022
  3. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine, 2025
  4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022
  5. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024
  6. He L et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Internal Medicine, 2022
WhatsAppCall Now